hepat
c
viru
hcv
infect
world
popul
highest
preval
part
africa
asia
past
standard
care
use
interferon
ribavirin
advers
effect
show
modest
efficaci
hcv
genotyp
spur
develop
direct
act
antivir
daa
daa
target
viral
protein
thu
better
toler
suffer
emerg
vial
resist
furthermor
daa
often
hcv
genotyp
specif
novel
drug
candid
target
host
factor
requir
hcv
propag
call
hosttarget
antivir
hta
promis
overcom
caveat
genet
barrier
resist
usual
consid
high
hta
hcv
genotyp
presum
use
host
factor
recent
data
howev
challeng
assumpt
least
hta
highlight
import
hosttarget
strategi
hepat
c
critic
discuss
opportun
risk
hepat
c
viru
hcv
chronic
infect
world
popul
highest
incid
africa
asia
patient
develop
sever
liver
diseas
year
contract
result
chronic
hepat
c
number
one
indic
liver
transplant
mani
countri
member
famili
flavivirida
hcv
particl
bear
plu
strand
rna
genom
glycoprotein
decor
envelop
hcv
classifi
six
epidemiolog
relev
genotyp
mani
subtyp
intergenotyp
sequenc
variabl
nucleotid
level
greater
high
divers
hcv
caus
fast
replic
rate
combin
error
prone
replic
machineri
owe
pronounc
genom
variat
hcv
evad
immun
recognit
becom
resist
antivir
drug
discoveri
hcv
etiolog
agent
caus
nona
nonb
hepat
chronic
hepat
c
patient
initi
treat
origin
treatment
effect
fraction
treat
patient
poorli
toler
requir
medic
week
ifn
base
therapi
regiment
refin
addit
nucleosid
analogu
ribavirin
usag
pegyl
deriv
increas
viral
respons
rate
construct
first
infecti
clone
creation
hcv
replicon
system
develop
novel
improv
therapeut
strategi
significantli
gain
momentum
search
better
drug
concentr
direct
act
antivir
daa
ie
agent
specif
interfer
viral
protein
requir
propag
new
cell
cultur
model
genotyp
isol
permit
analysi
complet
viral
replic
cycl
cell
cultur
aid
effort
sinc
first
two
daa
inhibitor
viral
proteas
boceprevir
telaprevir
market
achiev
respons
rate
genotyp
patient
combin
ribavirin
howev
although
tripl
therapi
clearli
improv
respons
rate
shorten
treatment
durat
side
effect
cost
exclus
licens
genotyp
patient
limit
applic
fortun
promis
virustarget
drug
clinic
trial
eg
inhibitor
phosphoprotein
viral
rnadepend
rna
polymeras
two
major
shortcom
virustarget
daa
emerg
resist
mutat
least
sever
class
daa
eg
proteas
inhibitor
pronounc
genotypedepend
efficaci
numer
vitro
studi
combin
grow
number
hcv
sequenc
data
patient
undergo
daa
treatment
underlin
viru
develop
drugresist
fit
restor
compensatori
mutat
thu
daa
typic
use
combin
therapi
current
standard
care
includ
one
two
avail
proteas
inhibitor
combin
ribavirin
ribavirin
ifn
contraind
mani
patient
moreov
caus
harsh
side
effect
limit
complianc
current
drug
develop
aim
futur
ifnspar
possibl
also
ribavirinfre
combinationtherapi
regimen
fact
numer
combin
therapi
involv
daa
differ
target
viru
clinic
develop
compar
www
clinicaltrialsgov
expect
trial
identifi
optim
drug
combin
given
variabl
hcv
combin
heterogen
patient
regard
comorbid
degre
liver
diseas
genet
background
like
sever
combin
therapi
regimen
evolv
tailor
toward
specif
patient
viru
group
emerg
third
group
antivir
call
hosttarget
antivir
hta
may
part
futur
combin
therapi
particular
hta
hold
promis
overcom
caveat
daa
hta
antibodi
rna
small
molecul
interfer
host
factor
need
hcv
propag
intens
research
past
decad
reveal
mani
molecular
detail
hcv
life
cycl
includ
usag
human
protein
microrna
entri
genom
replic
particl
assembl
andor
releas
knowledg
allow
target
design
numer
hta
promis
clinic
trial
result
tabl
hosttarget
antivir
strategi
assum
two
major
advantag
first
resist
barrier
hosttarget
therapi
suppos
high
sinc
host
factor
genet
stabl
except
critic
discuss
specif
chapter
second
usag
host
factor
thought
independ
hcv
genotyp
thu
hta
pangenotyp
activ
importantli
assumpt
fulli
support
experiment
evid
yet
cultur
system
genotyp
genotyp
avail
interfer
hcv
entri
factor
strategi
block
de
novo
infect
cell
fig
therefor
promis
drug
prevent
therapi
chronic
hepat
c
patient
undergo
liver
transplant
inde
reinfect
liver
graft
tissu
univers
unfortun
diseas
progress
transplant
commonli
acceler
hepat
c
treatment
virustarget
entri
blocker
ie
neutral
antibodi
hcv
glycoprotein
unfavor
variabl
among
hcv
protein
due
error
prone
viral
replic
infect
individu
carri
swarm
relat
viral
variant
quasispeci
may
compris
virus
escap
neutral
antibodi
consequ
strong
need
develop
hta
interf
viru
entri
advanc
entryblock
compound
small
molecul
inhibitor
term
itx
oral
bioavail
drug
show
good
safeti
profil
clinic
trial
subject
clinic
phase
studi
treatment
naiv
chronic
genotyp
patient
patient
show
virolog
respons
howev
posttranspl
set
better
efficaci
profil
possibl
preclin
test
use
hcv
pseudotyp
itx
broad
specif
genotyp
confirm
conserv
among
viral
genotyp
rais
hope
molecul
like
itx
could
pangenotyp
hcv
entri
inhibitor
bind
studi
involv
solubl
truncat
protein
indic
itx
interfer
interact
like
reason
antivir
activ
vitro
resist
select
reveal
singl
nucleotid
chang
lead
amino
acid
substitut
hcv
render
hcv
insensit
itx
one
hand
demonstr
hcv
theori
evad
hta
therapi
mutat
viral
bind
partner
target
host
factor
fact
suggest
low
genet
barrier
resist
hand
residu
highli
conserv
among
sequenc
hcv
isol
one
report
sequenc
lo
alamo
nation
laboratori
hcv
databas
show
aspart
acid
posit
notabl
mutat
report
upon
long
term
passag
viru
tissu
cultur
character
reveal
render
viru
highli
suscept
neutral
serum
igg
chronic
hcvinfect
patient
therefor
immunemedi
constraint
may
prevent
viru
develop
type
itx
resist
vivo
moreov
itx
resist
viru
still
sensit
proteas
inhibitor
argu
itx
could
use
combin
virustarget
daa
final
patient
receiv
itx
compar
short
durat
posttranspl
set
risk
resist
emerg
may
low
nevertheless
care
monitor
viral
variant
emerg
vivo
applic
compound
critic
apart
drug
resist
expect
caveat
target
host
molecul
possibl
endogen
function
side
effect
appear
minim
itx
report
advers
side
effect
itx
inhibit
mediat
high
densiti
lipoprotein
hdl
uptak
lead
increas
serum
hdl
level
fact
itx
origin
test
antiatherogen
compound
lastli
remain
determin
whether
host
genet
varianc
could
affect
itx
inhibit
recent
studi
suggest
sever
labgener
variant
effici
support
hcv
cell
entri
given
itx
compet
hcv
bind
like
compound
inhibit
variant
futur
work
particular
natur
occur
variant
clarifi
assumpt
summari
itx
promis
small
molecul
pangenotyp
hta
prevent
combin
therapi
posttranspl
hepat
c
patient
apart
small
molecul
entri
factor
block
antibodi
effici
inhibit
hcv
entri
preclin
develop
advanc
antibodi
target
recent
report
two
neutral
antibodi
block
hcv
infect
direct
celltocel
spread
vitro
vivo
notabl
fig
hcv
life
cycl
critic
host
factor
intervent
hcv
requir
host
protein
rna
life
cycl
offer
sever
point
intervent
use
hta
initi
hcvlipoviroparticl
attach
ldlr
heparan
sulfat
proteoglycan
hspg
surfac
hepatocyt
follow
coordin
uptak
requir
essenti
entri
factor
cldn
ocln
latter
four
entri
factor
target
specif
antibodi
small
molecul
like
itx
block
interact
clinic
phase
develop
accessori
factor
includ
receptor
tyrosin
kinas
transferrin
receptor
cholesterol
receptor
provid
altern
target
entri
blockag
intern
particl
uncoat
hcv
rna
genom
replic
special
cytosol
compart
term
membran
web
format
replic
complex
aid
host
viral
protein
inhibit
host
chaperon
cypa
cyclosporin
deriv
alisporivir
affect
function
viral
protein
therebi
inhibit
hcv
replic
alisporivir
current
test
clinic
phase
respect
host
lipid
kinas
requir
membran
web
format
inhibit
small
molecul
like
abolish
hcv
replic
third
class
replic
hta
compris
antagomir
host
microrna
bind
stabil
hcv
rna
genom
facilit
translat
moreov
involv
hcv
rna
replic
discuss
sequestr
miravirsen
clinic
phase
hta
strongli
suppress
viral
titer
human
liver
xenotranspl
mous
model
upascid
antibodi
prevent
hcv
infect
prophylact
set
five
antibodi
dosag
given
period
two
week
start
one
day
prior
infect
howev
viral
rebound
occur
least
one
week
termin
antibodi
treatment
suggest
twoweek
treatment
insuffici
elimin
viru
peripher
reservoir
threeday
postinfect
set
antibodi
prevent
infect
three
five
mice
reduc
viral
dissemin
remain
two
mice
similar
itx
antibodi
pangenotyp
show
advers
side
effect
thu
present
altern
option
prevent
therapi
futur
studi
show
whether
therapi
effici
broad
rang
orthotrop
liver
transplant
patient
contrast
antibodi
antibodi
block
hcv
infect
prophylact
set
xenotranspl
upascid
mous
model
suggest
target
superior
blockag
although
reason
clear
discrep
may
point
differenti
role
entri
factor
viru
transmiss
vitro
data
indic
hcv
transmit
cellfre
secret
viru
particl
also
direct
celltocel
transmiss
neighbor
cell
latter
mode
infect
may
particularli
relev
vivo
could
facilit
viral
escap
neutral
antibodi
notabl
absolut
essenti
infect
cellfre
viru
import
direct
celltocel
transmiss
disput
one
hand
fofana
et
al
identifi
antibodi
whichat
least
vitroalso
interfer
celltocel
spread
epitop
antibodi
current
remain
elus
find
rais
hope
develop
antibodi
postinfect
treatment
could
possibl
hand
recent
evid
confirm
facilit
absolut
essenti
celltocel
transmiss
vitro
hold
true
vivo
absenc
essenti
role
celltocel
spread
may
limit
efficaci
antibodi
compar
antibodi
target
entri
factor
critic
cellfre
celltocel
transmiss
mention
neutral
antibodi
potent
repress
celltocel
transmiss
vitro
human
mice
taken
togeth
result
suggest
import
direct
celltocel
spread
turn
explain
target
block
hcv
infect
vivo
effect
antibodi
bind
effici
block
hcv
entri
vitro
may
thu
anoth
promis
avenu
clinic
develop
notabl
substitut
lack
human
nonliv
cell
although
origin
assum
broad
tropism
toward
differ
member
cldn
protein
famili
common
hcv
isol
notion
recent
challeng
use
cell
line
express
either
molecul
haid
et
al
show
test
viral
strain
effici
use
strain
also
use
importantli
virus
capabl
use
fulli
neutral
antibodi
cell
coexpress
modest
level
find
point
toward
possibl
viral
escap
agent
viral
strain
broad
cldntropism
howev
fofana
et
al
unabl
observ
addit
inhibitori
effect
combin
antibodi
cell
challeng
hcv
discrep
might
result
use
host
cell
line
differ
six
express
level
notabl
primari
human
hepatocyt
donor
express
low
detect
cell
surfac
transcript
express
highli
variabl
hcv
patient
deriv
liver
biopsi
thu
potenti
risk
viral
escap
strategi
via
use
may
depend
viral
strain
also
host
determin
ie
differenti
abund
clearli
relev
viral
cldn
tropism
potenti
implic
develop
strategi
requir
investig
eg
xenotranspl
mice
human
hepatocyt
donor
distinct
express
asid
aspect
relat
efficaci
potenti
viral
escap
possibl
side
effect
anticldn
treatment
care
consid
current
vitro
data
suggest
endogen
function
remain
unalt
upon
antibodi
treatment
consequ
side
effect
treatment
expect
low
confirm
assumpt
preclin
model
critic
final
evalu
therapi
fourth
essenti
entri
factor
ocln
neutral
antibodi
report
date
howev
ocln
defici
mice
sever
phenotyp
includ
growth
retard
infertil
bone
thin
preclin
test
need
care
investig
possibl
side
effect
oclntarget
human
conclus
small
molecul
inhibitor
antibodi
target
advanc
hcv
entrytarget
agent
given
essenti
pangenotyp
role
cellfre
celltocel
transmiss
blockag
hold
promis
welltoler
therapi
prevent
allograft
infect
chronic
hepat
c
transplant
patient
apart
four
essenti
entri
factor
addit
molecul
shown
involv
hcv
cell
entri
includ
attach
factor
like
glucosaminoglycan
low
densiti
lipoprotein
receptor
ldlr
receptor
tyrosin
kinas
niemanpick
transferrin
receptor
multitud
host
factor
offer
numer
level
interfer
fig
among
promin
entri
cofactor
two
receptor
tyrosin
kinas
epiderm
growth
factor
receptor
egfr
ephrin
inhibit
egfr
use
small
molecul
erlotinib
dansatinib
block
hcv
entri
vitro
nm
compound
human
liver
chimer
mous
model
daili
prevent
erlotinib
treatment
reduc
serum
titer
hcv
approxim
tenfold
compar
placebo
treat
anim
viral
titer
rebound
serum
titer
control
anim
shortli
treatment
termin
togeth
find
provid
evid
erlotinib
least
partial
repress
hcv
infect
vivo
moreov
vitro
erlotinib
inhibit
cellfre
celltocel
transmiss
hcv
silenc
egfr
suggest
usag
egfr
hcv
genotyp
independ
howev
erlotinib
abl
fulli
ablat
hcv
cell
entri
vivo
whether
viru
escap
type
treatment
resist
mutat
current
clear
advers
effect
erlotinib
approv
anticanc
drug
includ
rash
diarrhea
lung
liver
kidney
problem
occurr
side
effect
line
fact
egfr
ubiquit
express
import
physiolog
function
includ
cell
prolifer
migrat
adhes
intens
side
effect
associ
erlotinib
mani
anticanc
agent
may
accept
malign
diseas
may
preclud
use
quit
immedi
life
threaten
condit
chronic
hcv
infect
lastli
polymorph
egfr
seem
correl
outcom
erlotinib
treatment
nonsmal
cell
lung
cancer
suggest
host
genet
varianc
could
also
influenc
antivir
therapi
outcom
summari
target
conserv
host
factor
less
critic
endogen
function
seem
favor
interfer
receptor
tyrosin
kinas
novel
mechanist
studi
role
egfr
reveal
signal
gtpase
hra
kinas
braf
hcv
receptor
complex
assembl
small
molecul
inhibitor
signal
molecul
exist
licens
anticanc
therapi
current
lack
preclin
vivo
data
use
antihcv
therapi
principl
target
hra
braf
offer
addit
mode
intervent
hcv
cell
entri
possibl
superior
efficaci
andor
reduc
side
effect
compar
erlotinib
second
less
frequent
discuss
hcv
entri
modul
cholesterol
receptor
niemannpick
protein
transmembran
molecul
express
apic
side
hepatocyt
mediat
cholesterol
absorpt
vitro
small
molecul
inhibitor
ezetimib
decreas
hcv
infect
least
fivefold
dose
human
liver
chimer
mous
model
ezitimib
prevent
infect
two
seven
mice
threeweek
dose
start
two
week
prior
infect
treatment
onset
two
day
prior
infect
surprisingli
prevent
hcv
infect
mice
although
seem
reduc
entri
hcv
genotyp
although
ezitimib
licens
cholesterollow
drug
littl
side
effect
overal
modest
efficaci
mice
favor
applic
inhibitor
monotherapi
howev
conjunct
hta
daa
ezitimib
may
use
improv
treatment
efficaci
taken
togeth
target
hcventri
modul
seem
less
effici
target
bona
fide
entri
factor
like
due
accessori
rather
essenti
role
hcv
cell
entri
still
compound
high
toler
could
valuabl
addit
combin
therapi
particular
orthotrop
liver
transplant
target
hcv
rna
replic
cyclophilin
blockag
hcv
entri
hepatocyt
promis
strategi
prevent
de
novo
infect
cell
target
hcv
replic
ie
amplif
viral
genom
hold
promis
effici
erad
hcv
alreadi
infect
tissu
hcv
replic
take
place
cytoplasm
host
cell
viru
encod
rnadepend
rna
polymeras
amplifi
plu
strand
rna
genom
end
hcv
induc
aid
host
factor
special
membran
compart
multipl
viral
protein
includ
nonstructur
protein
host
factor
assembl
hcv
replic
complex
henc
induct
assembl
function
hcv
replic
complex
involv
numer
host
factor
offer
multipl
target
intervent
cyclophilin
b
cypb
one
first
host
factor
report
crucial
hcv
replic
cyclophilin
highli
conserv
peptidylprolyl
isomeras
catalyz
isomer
peptid
bond
prolin
residu
tran
ci
transform
either
aid
fold
newli
synthes
protein
chang
structur
alreadi
fold
protein
interestingli
cyclophilin
essenti
replic
factor
number
virus
includ
hiv
herp
simplex
viru
vaccinia
viru
vesicular
stomat
viru
coronaviru
context
hcv
replic
recent
evid
indic
cyclphilin
cypa
rather
cypb
use
hcv
cofactor
isomeras
activ
cypa
essenti
function
moreov
biochem
genet
analys
reveal
interact
subdomain
cypa
could
promot
viral
protein
fold
regul
polyprotein
process
therebi
facilit
rna
replic
target
cypa
cyclic
polypeptid
immunosuppress
agent
cyclosporin
csa
prevent
interact
cypa
across
viral
genotyp
strong
antihcv
activ
vitro
fig
csa
antivir
also
immunosuppress
sinc
csacypa
complex
inhibit
calcineurin
therebi
suppress
helper
cell
dual
role
stimul
develop
deriv
retain
antivir
activ
without
immunosuppress
current
numer
cypa
inhibitor
exclus
antivir
effect
preclin
clinic
trial
among
alisporivir
debio
extens
studi
drug
candid
alisporivir
show
effici
reduct
viral
load
depend
studi
genotyp
monotherapi
moreov
combin
result
addit
effect
phase
clinic
trial
combin
tripl
therapi
incid
advers
effect
low
thereaft
phase
trial
genotyp
patient
initi
soon
halt
fda
due
occurr
pancreat
one
fatal
outcom
upon
treatment
ifn
alisporivir
therefor
ifnalisporivir
combin
preclud
futur
clinic
develop
howev
trial
ifnfre
alisporivir
treatment
regimen
improv
safeti
profil
resum
apart
broad
hcv
genotyp
specif
alisporivir
seem
act
independ
host
genet
background
recent
studi
investig
host
variabl
cypa
found
rare
nonsynonym
snp
cypa
render
cell
larg
resist
hcv
infect
also
residu
replic
still
sensit
cypa
inhibit
lastli
cypa
inhibitor
appear
high
genet
barrier
develop
viral
resist
vivo
howev
vitro
resist
toward
anticyclophilin
compound
select
either
long
term
viral
passag
presenc
drug
select
virus
host
cell
reduc
cyclophilin
abund
current
describ
resist
mutat
map
domain
support
concept
cypa
facilit
hcv
replic
via
modif
function
interestingli
resist
mutat
locat
cterminu
close
cleavag
site
moreov
alter
shown
modul
polyprotein
cleavag
site
support
notion
cyclophilin
fine
tune
protein
fold
process
requir
optim
polyprotein
cleavag
turn
replic
complex
assembl
although
mutat
describ
vitro
confer
high
degre
viral
resist
part
shift
valu
far
resist
mutat
describ
treatment
hcv
patient
fact
alisporivir
monotherapi
viral
breakthrough
observ
suggest
vivo
barrier
viral
resist
high
notabl
studi
one
alisporivir
null
respond
identifi
howev
absenc
viral
respons
case
due
viral
host
resist
clear
merit
investig
possibl
explan
rare
treatment
failur
could
recent
report
second
antivir
mechan
cyclophilin
deriv
independ
complex
disrupt
altern
nonimmunosupress
cypa
inhibitor
current
clinic
phase
trial
seem
reconstitut
ifn
signal
turn
increas
innat
antivir
defens
first
evid
stem
clinic
trial
monotherapi
chronic
hcv
genotyp
infect
patient
context
dose
depend
repress
viral
load
also
caus
increas
plasma
level
ifn
well
synthas
key
ifn
stimul
gene
isg
meanwhil
two
possibl
molecular
link
ifn
isg
induct
disclos
bobardt
colleagu
report
cypa
bind
ifn
regulatori
factor
compet
cypa
bind
dna
bind
part
transcript
factor
ifnstimul
gene
factor
critic
transmit
ifninduc
jak
stat
signal
nucleu
express
isg
importantli
inhibit
cypa
cyclosporin
prevent
complex
format
therebi
enhanc
ifninduc
express
isg
hand
watashi
et
al
note
ifntreat
hcv
infect
cell
decreas
phosphoryl
protein
kinas
r
pkr
sinc
phosphoryl
pkr
downregul
express
isg
level
translat
possibl
repress
pkr
phosphoryl
enhanc
translat
isg
therefor
blockad
cypa
may
increas
express
isg
antivir
activ
ifn
transcript
posttranscript
mechan
interest
dissect
extent
mechan
contribut
antivir
activ
cypatarget
strategi
antivir
mechan
share
differ
compound
target
cypa
provid
concern
regard
safeti
cypatarget
hta
elimin
agent
could
attract
pangenotyp
therapeut
target
hcv
rna
replic
phosphatidylinositol
iii
alpha
genom
wide
rna
interfer
screen
depth
cell
cultur
replic
assay
hcv
replicon
full
length
infecti
viru
reveal
numer
addit
host
depend
factor
could
principl
serv
antivir
target
one
promin
consist
identifi
host
factor
hcv
replic
protein
belong
famili
enzym
catalyz
phosphoryl
lipid
posit
four
inositol
moieti
result
phosphoinositid
pi
resid
cytosol
leaflet
vesicl
organel
membran
play
critic
role
recruit
activ
signal
protein
date
four
mammalian
phosphatidylinositol
known
differ
subcellular
local
creat
distinct
pi
pool
thu
contribut
vesicl
traffick
lipid
transport
locat
endoplasm
reticulum
plasma
membran
found
primari
mammalian
influenc
hcv
replic
notabl
silenc
dramat
reduc
hcv
rna
replic
concomitantli
result
cluster
distribut
viral
nonstructur
protein
aberr
ultrastructur
membran
web
accumul
membran
vesicl
site
hcv
rna
replic
interestingli
hcv
directli
interact
interact
stimul
kinas
activ
enzym
recent
bind
site
map
highli
conserv
region
within
domain
moreov
although
lipid
kinas
report
studi
modul
phosphoryl
statu
although
current
unclear
effect
direct
indirect
like
regul
phosphoryl
local
accumul
phosphatidylinositol
pool
import
hcv
replic
sinc
reduc
level
viral
mutat
ablat
interact
caus
aberr
ultrastructur
hcv
replic
complex
reason
assum
interplay
essenti
proper
assembl
function
membran
bound
hcv
replic
complex
date
two
studi
address
target
interact
enzymat
activ
would
use
strategi
control
hcv
rna
replic
bianco
et
al
report
quinazolin
target
kinas
activ
vitro
within
liver
cell
interestingli
quinazolin
compound
previous
report
hcv
inhibitor
base
put
resist
mutat
within
presum
target
none
mutat
howev
shown
confer
resist
quinazolin
nevertheless
given
interact
observ
anilin
quinazolin
moieyti
frequent
present
kinas
inhibitor
seem
like
target
therebi
inhibit
hcv
replic
addit
compel
evid
interfer
hcv
replic
report
vaillancourt
use
kinas
assay
screen
compound
variou
specif
inhibitor
enzym
identifi
molecul
belong
three
differ
chemotypesal
unrel
quinazolin
compound
describ
abovepot
repress
kinas
activ
vitro
hcv
replic
replicon
assay
importantli
inhibit
kinas
exclud
vitro
assay
involv
variou
kinas
lipid
kinas
studi
also
reveal
select
toward
compar
besid
antivir
activ
compound
correl
degre
inhibit
support
notion
compound
antivir
due
blockad
final
viral
resist
select
reveal
specif
mutat
within
cterminu
domain
reduc
sensit
hcv
molecul
interestingli
resist
mutat
permit
effici
hcv
replic
cell
silenc
highlight
confer
reduc
depend
hcv
function
inde
compound
target
combin
observ
ultrastructur
analys
replic
complex
cell
silenc
mutant
virus
reduc
reason
assum
recruit
enzymat
activ
crucial
proper
assemblymorpholog
function
hcv
replic
complex
fig
inhibitor
disturb
bind
viral
resist
molecul
attain
reduc
depend
due
alter
function
andor
note
kinas
inhibitor
resist
mutat
decreas
hcv
rna
replic
endogen
level
thu
resist
like
link
decreas
viral
fit
may
contain
emerg
mutat
vivo
explor
physiolog
role
vivo
villaincourt
et
al
creat
knockout
mice
condit
lesion
gene
locu
unfortun
induct
gene
defect
homozyg
anim
caus
lethal
gastrointestin
disord
therefor
critic
physiolog
role
possibl
side
effect
therapi
target
enzym
probabl
limit
develop
class
inhibitor
futur
hcv
therapi
target
hcv
rna
replic
apart
proteinac
host
factor
hcv
requir
microrna
effici
replic
microrna
mirna
nucleotid
long
noncod
rna
molecul
typic
bind
mrna
arrest
translat
induc
mrna
cleavag
degrad
thu
emerg
power
regul
gene
express
surprisingli
virus
evolv
exploit
cellular
machineri
fact
sever
dna
virus
herpesvirus
encod
viral
mirna
use
tune
express
host
viral
rna
although
hcv
like
rna
virus
encod
mirna
depend
rna
molecul
uniqu
way
thu
offer
potenti
target
antivir
intervent
specif
liverspecif
mirna
regul
numer
gene
involv
fatti
acid
cholesterol
metabol
bind
translat
region
hcv
rna
genom
two
tandem
bind
site
character
site
specif
bind
report
facilit
translat
viral
rna
stabil
hcv
rna
lead
accumul
vial
genom
although
presenc
absolut
essenti
hcv
rna
replic
high
abund
crucial
effici
replic
thu
liverspecif
express
like
contribut
overt
hepatotrop
hcv
inactiv
use
complementari
lock
nucleic
acidmodifi
oligonucleotid
miravirsen
reduc
hcv
titer
vitro
hcv
infect
chimpanze
log
fig
moreov
broad
hcv
genotyp
specif
vitro
suggest
wide
usag
miravirsenbas
therapi
patient
genet
engin
variant
hcv
lack
bind
site
resist
miravirsen
still
viabl
although
show
fit
loss
notabl
monotherapi
clinic
trial
cell
cultur
far
resist
mutat
miravirsen
emerg
therefor
barrier
viral
resist
drug
seem
high
regard
side
effect
preclin
studi
chimpanze
suggest
miravirsen
treatment
reduc
serum
cholesterol
level
neither
induc
toxic
histopatholog
chang
importantli
recent
phase
clinic
trial
five
weekli
inject
miravirsen
reduc
viral
titer
log
without
advers
side
effect
resist
emerg
fact
treat
patient
clear
hcv
rna
miravirsen
monotherapi
furthermor
miravirsen
treatment
chimpanze
human
elicit
continu
prolong
antivir
effect
last
sever
week
cessat
therapi
miravirsen
administr
current
possibl
less
attract
parenter
rout
advantag
miravirsen
therapi
could
longlast
effect
pharmacokinet
patient
studi
reveal
day
plasma
halflif
suggest
miravirsen
may
administ
per
month
collect
vitro
vivo
data
provid
firm
evid
target
efficaci
least
transient
treatment
regimenswel
toler
futur
therapeut
option
spite
encourag
initi
result
recent
find
regard
physiolog
role
warrant
caution
mice
lack
viabl
develop
steatohepat
fibrosi
hepatocellular
carcinoma
importantli
reconstitut
reduc
tumor
incid
demonstr
act
tumor
suppressor
mice
date
molecular
detail
antitumor
activ
unclear
certainli
research
need
exclud
transient
sequestr
could
promot
tumorigenesi
sever
advers
side
effect
occur
long
halflif
miravirsen
make
serum
level
difficult
control
particular
sinc
readili
avail
mean
termin
drug
action
apart
note
caution
regard
host
target
interest
explor
associ
chronic
hcv
infect
hepatocellular
carcinoma
connect
viru
usurp
sequest
conclus
miravirsen
pangenotyp
effect
hta
low
risk
resist
emerg
critic
evalu
advers
effect
clarifi
miravirsen
part
futur
inffre
regimen
hcv
cell
base
assay
dissect
pathway
step
hcv
particl
assembl
viru
releas
avail
rel
short
time
therefor
hosttarget
antivir
strategi
focus
late
stage
viral
replic
cycl
least
advanc
first
report
assembl
blocker
iminosugar
target
er
enzym
requir
hcv
glycoprotein
fold
matur
howev
compar
modest
efficaci
iminosugar
celgosivir
genotyp
patient
led
termin
clinic
trial
nevertheless
recent
report
highlight
sever
cellular
cofactor
assist
viru
product
may
futur
target
antivir
therapi
known
long
time
hcv
travel
blood
stream
tight
associ
lipoprotein
moreov
care
proteom
analysi
serumderiv
hcv
reveal
presenc
apolipoprotein
e
apo
apob
lipoviroparticl
cell
cultur
deriv
hcv
hcvcc
apo
report
associ
particl
lipid
composit
hcvcc
found
resembl
one
low
densiti
lipoprotein
vldl
given
interplay
hcv
lipoprotein
surpris
host
factor
involv
assembl
releas
vldl
seem
aid
product
infecti
viral
progeni
specif
microsom
triglycerid
transfer
protein
mttp
involv
load
lipid
onto
nascent
apob
well
apob
apo
compon
vldl
report
contribut
viru
product
consequ
modul
vldl
product
secret
emerg
potenti
antivir
compound
includ
mttp
apob
inhibitor
preclin
result
avail
show
modest
antivir
activ
notabl
recent
evid
suggest
among
differ
factor
vldl
pathway
implic
hcv
viru
product
apo
absolut
essenti
sinc
product
infecti
hcv
reconstitut
engin
human
kidney
deriv
cell
line
produc
vldl
lack
endogen
express
mttp
apob
although
hcv
particl
minim
lipoprotein
coat
may
infecti
natur
hcv
therefor
possibl
hcv
could
escap
mttp
apob
target
strategi
hand
find
favor
develop
apoetarget
strategi
moreov
apo
associ
hcv
particl
play
critic
role
viral
cell
entri
facilit
attach
virion
cellular
heparin
sulfat
proteoglycan
apoetarget
compound
may
arrest
assembl
entri
hcv
particl
besid
host
factor
vldl
pathway
addit
cellular
protein
recent
shown
contribut
viru
product
instanc
cellular
lipid
modifi
enzym
like
diacylglycerol
acyl
transferas
cytosol
phospholipas
contribut
product
infecti
hcv
progeni
specif
catalyz
triglycerid
biosynthesi
therebi
promot
lipid
droplet
format
hcv
thought
assembl
surfac
lipid
droplet
vitro
inhibit
silenc
shown
reduc
hcv
genotyp
assembl
releas
limit
traffick
hcv
core
orgenel
intriguingli
upon
inhibit
relat
enzym
seem
compens
endogen
function
vitro
find
indic
advers
effect
inhibit
may
low
moreov
inhibitor
develop
treatment
obes
display
littl
advers
effect
second
lipid
modifi
enzym
report
involv
hcv
assembl
cleav
glycerophospholipid
arachidon
acid
therebi
alter
membran
fluiditi
curvatur
releas
arachidon
acid
precursor
inflammatori
mediat
henc
inhibitor
like
preclin
develop
treatment
inflammatori
disord
recent
studi
menzel
et
al
inhibit
assembl
releas
hcv
genotyp
vitro
treatment
arachidon
acid
restor
hcv
infect
thu
inhibitor
present
possibl
avenu
assembl
blockag
futur
preclin
test
could
connect
exist
pipelin
pyrrolidin
antiinflammatori
agent
summari
identif
host
lipoprotein
enzym
requir
hcv
assembl
releas
provid
novel
hta
develop
option
current
lack
knowledg
possibl
side
effect
efficaci
hta
vivo
futur
preclin
work
need
elucid
compound
target
last
step
hcv
life
cycl
merit
develop
possibl
antihcv
therapeut
year
base
therapi
hepat
c
novel
treatment
regimen
develop
rapidli
sinc
approv
first
daa
increas
understand
molecular
virolog
hcv
usag
host
factor
propag
led
discoveri
multitud
antivir
target
initi
effort
focus
inhibit
viral
enzym
viral
structur
protein
reflect
overal
distribut
fdaapprov
antivir
drug
fda
list
virustarget
drug
includ
hiv
influenza
viru
hta
latter
howev
gain
increas
attent
often
high
genet
barrier
resist
emerg
display
broad
specif
variou
genotyp
subtyp
given
viru
promin
hta
hcv
includ
entri
inhibitor
replic
inhibitor
preclin
studi
howev
start
reveal
propos
advantag
hta
appli
rare
case
genotyp
specif
observ
differ
genotyp
engag
differ
host
factor
exemplifi
usag
hcv
entri
case
viru
acquir
resist
mutat
lead
usag
alter
bind
site
host
factor
instanc
mutat
confer
resist
cypatarget
drug
find
suggest
even
hta
use
combin
therapi
drug
obviou
caveat
hta
possibl
side
effect
consequ
preclin
earli
clinic
studi
need
care
evalu
dose
treatment
durat
hosttarget
therapi
note
report
side
effect
hta
clinic
phase
like
itx
low
howev
caution
warrant
termin
alisporivirifn
clinic
trial
show
summari
least
hta
therapi
appear
superior
side
effect
profil
compar
past
standard
care
show
strong
sometim
intoler
advers
effect
week
treatment
period
lastli
begin
understand
role
host
genet
hcv
infect
best
exampl
polymorph
upstream
gene
correl
develop
chronic
treatment
respons
futur
research
need
address
whether
hcv
host
factor
genet
divers
human
popul
impact
polymorph
hcv
infect
respons
hta
treatment
nonetheless
era
virusand
hosttarget
antivir
hcv
hold
big
promis
chronic
hcv
patient
mani
previou
nonrespond
treat
new
proteas
inhibitor
combin
patient
undergo
treatment
benefit
reduc
side
effect
shorten
therapi
durat
futur
develop
hta
novel
possibl
allor
combin
therapi
expect
increas
qualiti
life
chronic
hcv
patient
certain
patient
group
eg
hiv
coinfect
individu
patient
late
stage
liver
diseas
might
requir
individu
therapi
thu
intens
research
daa
hta
need
find
effect
drug
combin
least
advers
effect
final
better
understand
host
viru
genet
divers
influenc
drug
efficaci
might
allow
person
treatment
futur
therebi
guarante
cost
effect
use
novel
drug
optim
therapi
outcom
individu
patient
conflict
interest
gisa
gerold
conflict
interest
declar
receiv
grant
german
academi
scienc
leopoldina
human
frontier
scienc
program
german
liver
foundat
thoma
pietschmann
paid
board
member
janssen
biotest
institut
receiv
grant
erc
dfg
helmholtz
associ
human
anim
right
inform
consent
articl
contain
studi
human
anim
subject
perform
author
paper
particular
interest
publish
recent
highlight
